CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis

被引：0
|
作者：
Minghuan Jiang
Joyce H. S. You
机构：
[1] The Chinese University of Hong Kong,School of Pharmacy, Faculty of Medicine
来源：
Cardiovascular Drugs and Therapy | 2017年 / 31卷
关键词：
Clopidogrel; Prasugrel; Ticagrelor; genotype; Acute coronary syndrome; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：39 / 49
页数：10
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of genotype-guided antiplatelet therapy in patients with acute coronary syndrome and planned percutaneous coronary intervention.
    Lin, Fang-Ju
    Patel, Vardhaman
    Ojo, Olaitan
    Rao, Sapna
    Yu, Shengsheng
    Zhan, Lin
    Touchette, Daniel R.
    PHARMACOTHERAPY, 2012, 32 (10): : E300 - E300
  • [22] Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
    Klein, Melissa D.
    Williams, Alexis K.
    Lee, Craig R.
    Stouffer, George A.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 647 - 652
  • [23] Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
    Zeling Cai
    De Cai
    Ruiwen Wang
    Heng Wang
    Ze Yu
    Fei Gao
    Yuansheng Liu
    Yingbo Kang
    Zhuomin Wu
    Scientific Reports, 11
  • [24] Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
    Cai, Zeling
    Cai, De
    Wang, Ruiwen
    Wang, Heng
    Yu, Ze
    Gao, Fei
    Liu, Yuansheng
    Kang, Yingbo
    Wu, Zhuomin
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review
    AlMukdad, Sawsan
    Elewa, Hazem
    Al-Badriyeh, Daoud
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (03) : 201 - 211
  • [26] The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
    Lyu, Si-Qi
    Yang, Yan-Min
    Zhu, Jun
    Wang, Juan
    Wu, Shuang
    Zhang, Han
    Shao, Xing-Hui
    Ren, Jia-Meng
    PLATELETS, 2020, 31 (08) : 971 - 980
  • [27] Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Rajachandran, Manu
    Lange, Richard A.
    CURRENT CARDIOLOGY REPORTS, 2024, 26 (07) : 675 - 680
  • [28] Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
    Kazi, Dhruv S.
    Garber, Alan M.
    Shah, Rashmee U.
    Dudley, R. Adams
    Mell, Matthew W.
    Rhee, Ceron
    Moshkevich, Solomon
    Boothroyd, Derek B.
    Owens, Douglas K.
    Hlatky, Mark A.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (04) : 221 - 232
  • [29] PANACEA OR PERSONALIZED MEDICINE? OPTIMIZING ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS
    Kazi, Dhruv
    Garber, Alan M.
    Shah, Rashmee
    Rhee, Ceron
    Moshkevich, Solomon
    Mell, Matthew W.
    Boothroyd, Derek
    Owens, Douglas K.
    Hlatky, Mark
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E348 - E348
  • [30] The cost-effectiveness of genetic testing for CYP2C19 variants to guide antiplatelet therapy with clopidogrel or prasugrel in R. Macedonia
    Nestorovska, A. Kapedanovska
    Naumovska, Z.
    Sterjev, Z.
    Grozdanova, A.
    Dimovski, A.
    Shuturkova, L.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 567 - 567
12345